company background image
RUBY

Rubius TherapeuticsNasdaqGS:RUBY Stock Report

Market Cap

US$1.5b

7D

-3.0%

1Y

247.9%

Updated

21 Oct, 2021

Data

Company Financials +
RUBY fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

RUBY Overview

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Rubius Therapeutics
Historical stock prices
Current Share PriceUS$16.28
52 Week HighUS$4.20
52 Week LowUS$38.71
Beta2.57
1 Month Change-16.38%
3 Month Change-25.22%
1 Year Change247.86%
3 Year Change-1.69%
5 Year Changen/a
Change since IPO-32.87%

Recent News & Updates

Jul 11

Our Read On Rubius Therapeutics

Today, we take our first in-depth look at Rubius Therapeutics which has developed a new class of cellular therapies called Red Cell Therapeutics. The company's pipeline has several candidates in development and Rubius recently addressed its current funding needs. A full investment analysis follows in the paragraphs below.

Shareholder Returns

RUBYUS BiotechsUS Market
7D-3.0%0.4%2.6%
1Y247.9%17.1%31.1%

Return vs Industry: RUBY exceeded the US Biotechs industry which returned 17.8% over the past year.

Return vs Market: RUBY exceeded the US Market which returned 31.5% over the past year.

Price Volatility

Is RUBY's price volatile compared to industry and market?
RUBY volatility
RUBY Beta2.57
Industry Beta0.98
Market Beta1

Stable Share Price: RUBY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: RUBY's weekly volatility has decreased from 20% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013248Pablo Cagnonihttps://www.rubiustx.com

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes.

Rubius Therapeutics Fundamentals Summary

How do Rubius Therapeutics's earnings and revenue compare to its market cap?
RUBY fundamental statistics
Market CapUS$1.46b
Earnings (TTM)-US$173.90m
Revenue (TTM)n/a

0x

P/S Ratio

-8.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RUBY income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$173.90m
Earnings-US$173.90m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.94
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio28.7%

How did RUBY perform over the long term?

See historical performance and comparison

Valuation

Is Rubius Therapeutics undervalued compared to its fair value and its price relative to the market?

5.53x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: RUBY ($16.28) is trading above our estimate of fair value ($10.96)

Significantly Below Fair Value: RUBY is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: RUBY is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: RUBY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RUBY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RUBY is overvalued based on its PB Ratio (5.5x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Rubius Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

17.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RUBY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RUBY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RUBY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RUBY is forecast to have no revenue next year.

High Growth Revenue: RUBY is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RUBY is forecast to be unprofitable in 3 years.


Past Performance

How has Rubius Therapeutics performed over the past 5 years?

-34.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RUBY is currently unprofitable.

Growing Profit Margin: RUBY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RUBY is unprofitable, and losses have increased over the past 5 years at a rate of 34.5% per year.

Accelerating Growth: Unable to compare RUBY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RUBY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: RUBY has a negative Return on Equity (-65.84%), as it is currently unprofitable.


Financial Health

How is Rubius Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: RUBY's short term assets ($304.3M) exceed its short term liabilities ($25.1M).

Long Term Liabilities: RUBY's short term assets ($304.3M) exceed its long term liabilities ($106.9M).


Debt to Equity History and Analysis

Debt Level: RUBY's debt to equity ratio (28.7%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if RUBY's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RUBY has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RUBY has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 36.6% each year.


Dividend

What is Rubius Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RUBY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RUBY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RUBY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RUBY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RUBY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Pablo Cagnoni (58 yo)

3.33yrs

Tenure

US$3,443,869

Compensation

Dr. Pablo J. Cagnoni, M.D., Ph D., is a Director at Turmeric Acquisition Corp. and Repertoire Immune Medicines, Inc. Dr. Cagnoni has been the Chief Executive Officer and Director of Rubius Therapeutics, In...


CEO Compensation Analysis

Compensation vs Market: Pablo's total compensation ($USD3.44M) is about average for companies of similar size in the US market ($USD3.51M).

Compensation vs Earnings: Pablo's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: RUBY's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: RUBY's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.2%.


Top Shareholders

Company Information

Rubius Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Rubius Therapeutics, Inc.
  • Ticker: RUBY
  • Exchange: NasdaqGS
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.462b
  • Shares outstanding: 89.77m
  • Website: https://www.rubiustx.com

Number of Employees


Location

  • Rubius Therapeutics, Inc.
  • 399 Binney Street
  • Suite 300
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 23:07
End of Day Share Price2021/10/21 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.